Trinity Biotech (TRIB) received notice from the Nasdaq Stock Market LLC that the company is not in compliance with Nasdaq Listing Rule ...

With substantial progress in developing its differentiated and innovative CGM and its significant market potential, Trinity Biotech’s board and management have determined that CGM technology and ...

The stock has a market cap of $12.48 million, a PE ratio of -0.31 and a beta of 1.20. Trinity Biotech has a twelve month low of $0.63 and a twelve month high of $3.55. An institutional investor ...

Shares of TRIB opened at $0.76 on Friday. Trinity Biotech has a twelve month low of $0.74 and a twelve month high of $3.55. The stock has a market cap of $13.72 million, a PE ratio of -0.34 and a ...

Trinity Biotech PLC (NASDAQ:TRIB), a leading diagnostic substances company with a market capitalization of $13.12 million, has successfully amended and restated its credit and guaranty agreement ...

DUBLIN, Ireland, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions ...

Trinity Biotech PLC (TRIB) reports a 3% revenue increase and outlines strategic initiatives for future growth and profitability. Trinity Biotech PLC (TRIB) reports a 14% revenue increase with ...

DUBLIN, Ireland, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, ...

DUBLIN - Trinity Biotech plc (NASDAQ:TRIB), a leader in diabetes management solutions currently trading at $0.86 per share, has announced significant enhancements in the performance of its ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Boston biotech’s series A follows a $15 million seed financing that closed in September 2024. That round was co-led by BVF Partners and KKR’s Dawn Biopharma, with participation from Salvia ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...